Abiopharma

🔍 JACKSON JOHN EARL (Executive)

Company: Main Street Capital CORP (MAIN)

Report Date: 2026-05-04

Detailed Transactions and Holdings:

• Acquired 85 shares of Common Stock at $56.39 per share (Direct)
  Date: 2026-04-15 | Code: J | equity_swap_involved: 0 | shares_owned_after: 81,955.07 | transaction_form_type: 5 | Footnotes: F1
• Acquired 213 shares of Common Stock at $57.83 per share (Direct)
  Date: 2026-04-15 | Code: J | equity_swap_involved: 0 | shares_owned_after: 82,168.45 | transaction_form_type: 5 | Footnotes: F1
• Acquired 538 shares of Common Stock (Direct)
  Date: 2026-05-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 82,706.45 | transaction_form_type: 4 | Footnotes: F2
• Acquired 1,345 shares of Common Stock at $55.76 per share (Direct)
  Date: 2026-05-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 84,051.50 | transaction_form_type: 4 | Footnotes: F3
• Acquired 9 shares of Common Stock at $57.382 per share (Direct)
  Date: 2026-04-15 | Code: J | equity_swap_involved: 0 | shares_owned_after: 2,016.00 | transaction_form_type: 5 | Footnotes: F1

Footnotes:

• F1: The reporting person acquired these shares under a dividend reinvestment plan, pursuant to a dividend reinvestment transaction exempt from Section 16 under Rule 16a-11.
• F2: Shares issued under the Main Street Capital Corporation Non-Employee Director Restricted Stock Plan.
• F3: Shares issued under the Main Street Capital Corporation Deferred Compensation Plan.